Nerivio REN is a safe, discreet wearable that can be worn without disrupting daily activities and it delivers migraine care by activating natural pain pathways to inhibit migraines and their associated symptoms.
The Annals of the Child Neurology Society recently published results from a prospective real-world evidence study evaluating the safety and efficacy of remote electrical neuromodulation (REN) as a treatment for migraine in children ages six to 11. The Nerivio REN wearable is the first FDA-cleared, non-drug treatment for both acute migraine attacks and prevention of migraine with or without aura in adolescents and adults ages 12 and older. Now, the treatment is currently under FDA review to potentially expand the indication to ages younger than 12.
Key Themes Behind This Trend
- Child-focused Health Tech
- Wearables designed specifically for young patients create opportunities to address unique pediatric health challenges.
- Non-pharmaceutical Migraine Solutions
- Innovative treatments like REN that focus on neuromodulation offer alternatives to traditional medication-based therapies.
- Real-world Evidence Research
- The use of real-world evidence studies to support the safety and efficacy of medical devices can accelerate regulatory approval processes.
Where This Applies
- Pediatric Healthcare
- Targeting younger demographics with specialized healthcare solutions addresses unmet needs in pediatric patient care.
- Wearable Technology
- Advancements in wearables that provide non-invasive treatment options mark a significant shift in how chronic conditions are managed.
- Remote Medical Devices
- The development of remote medical devices enhances patient autonomy and reduces dependency on medication.
